Firuglipel

DB19506InvestigationalSmall molecule

Firuglipel is a small molecule drug. Firuglipel is under investigation in clinical trial NCT02647320 (12-Week Study of DS-8500a in Subjects With Type 2 Diabetes Mellitus on Metformin). Firuglipel has a... Firuglipel has a monoisotopic molecular weight of 467.19 Da.

Mechanism: Pharmacologically active on Glucose-dependent insulinotropic receptor
Curator reviewed
Formula / weight: C₂₅H₂₆FN₃O₅ · 467.497 g/mol (avg)
Code names: DS-8500A

Resolves to

Compound

UNII08P99TX229CAS1371591-51-3ChEMBLCHEMBL5314955ChEBI759646PubChem56959560

Structure

InChIKeyLRXRIKVDAVVQCP-SPLOXXLWSA-NSMILESCC[C@@H](OC1=CC=C(C=C1)C(=O)C1CC1)C1=NC(=NO1)C1=CC(F)=C(C=C1)C(=O)N[C@H](C)CO

Targets

Q8TDV5GPR119

What you can answer from here — as of September 23, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

6Clinical trialsPhase, status and sponsor resolved per trial

4+ReferencesStructured and connected to the statements they support

Which drugs share a target with Firuglipel, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account